Drug Metabolism in Pharmaceutical Drug Discovery and Development | An ISSX 2021 Short Course

The course is designed to include a number of topics that both cover and branch out from our traditional liver and small-molecule focused mindset. The unifying focus through each topic would be to discuss how biotransformation work directly influences drug discovery and development in industry.

Co-Chairs: Valerie Kramlinger, Novartis, Cambridge, Massachusetts, USA and Ana Vergara, Merck & Co., West Point, Pennsylvania, USA

Drug-metabolizing Enzymes – What are They?
Klarissa Jackson, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA

Application of Drug-metabolizing Enzyme Knowledge in Early Drug Discovery Towards Lead Optimization
Valerie Kramlinger, Novartis, Cambridge, Massachusetts, USA

Application of Drug Metabolism Science in Resolving ADME/TOX Liabilities in Preclinical Discovery
Amit Kalgutkar, Pfizer Inc., Cambridge, Massachusetts, USA

Metabolism of Multi-modality Drug Candidates: Which Concepts Translate?
Brooke Rock, Amgen, Inc., South San Francisco, California, USA

Antibody Drug Conjugates: Biotransformation in Lead Optimization and Selection
Maribel Beaumont, Merck & Co., Inc., South San Francisco, California, USA